Lite Strategy (LITS) investor relations material

Company overview and business model

• Operates as a pharmaceutical company focused on novel cancer therapies and has expanded into pre-clinical programs for non-oncologic diseases in 2026.

• Holds Litecoin (LTC) tokens as a primary reserve asset, implementing a digital asset treasury strategy to diversify reserves and enhance capital efficiency.

• Pipeline includes voruciclib (oral CDK9 inhibitor), zandelisib (oral PI3K8 inhibitor), and previously ME-344 (sold in 2024).

• Engages in covered call options on LTC holdings to generate incremental liquidity and income.

Financial performance and metrics

• Closed a $100 million PIPE in July 2025, issuing 23,216,898 shares at $3.42 per share and pre-funded warrants for 6,022,869 shares at $3.4199 per warrant.

• As of September 22, 2026, 30,407,268 shares of common stock are outstanding, with 32,296,338 shares expected after full warrant exercise.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders.

• May receive up to $132.23 from GSR Warrant exercises and $56.67 from Advisory Warrant exercises, to be used for general corporate purposes.

• Substantially all net proceeds from prior offerings have been used to purchase Litecoin.